{"entity":{"id":"epsilogen","kind":"company","name":"Epsilogen","aka":[],"tldr":"Epsilogen develops antibody medicines of the IgE class, a type of antibody normally involved in allergy, to rally the immune system against cancer. Its lead medicine, MOv18 IgE, is in an early trial in ovarian cancer that has stopped responding to platinum chemotherapy.","summary":"Epsilogen Ltd is based at ARC West London in Hammersmith and describes itself as a pan-isotype antibody company for cancer. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is described by the company as the first IgE therapeutic to enter the clinic. The company-sponsored phase 1b trial EPS101-10-02 (NCT06547840) tests MOv18 IgE in folate receptor alpha-expressing platinum-resistant ovarian cancer, with conditions also listing triple-negative breast cancer and endometrial cancer. In April 2026 the company reported ARPA-H backing for engineered IgA antibody therapeutics. Its first registered cancer trial, NCT06547840, was posted on ClinicalTrials.gov in August 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://epsilogen.com/"},{"label":"ClinicalTrials.gov: phase 1b trial of MOv18 IgE (NCT06547840)","url":"https://clinicaltrials.gov/study/NCT06547840"},{"label":"Epsilogen: ARPA-H backs engineered IgA antibodies (April 2026)","url":"https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/"}],"tags":[],"related":[],"cancers":["platinum-resistant-ovarian-cancer","tnbc-metastatic"],"sections":["immunotherapy"],"technologies":["monoclonal-antibody"],"targets":["folr1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","No financing rounds are stated on the pages read; the press release list loads dynamically and could not be read.","MOv18 IgE had an earlier first-in-human study not sponsored by the company; the company's own first registry study is the 2024 phase 1b.","Company website read on 29 October 2026."],"hq":"London","country":"GB","companyType":"biotech","website":"https://epsilogen.com/","investors":[],"funding":[]},"route":"/companies/epsilogen/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"}]}}